Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $11.64 Average Price Target from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average recommendation of “Buy” by the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $11.6364.

TSHA has been the subject of several recent research reports. Canaccord Genuity Group raised their target price on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Needham & Company LLC raised their price target on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Chardan Capital restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the sale, the insider owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Vestal Point Capital LP grew its position in Taysha Gene Therapies by 150.0% during the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after buying an additional 8,250,000 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at about $11,178,000. Barclays PLC grew its position in shares of Taysha Gene Therapies by 1,042.8% in the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $20,471,000. Finally, State Street Corp grew its position in shares of Taysha Gene Therapies by 49.1% in the fourth quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Down 5.4%

Shares of Taysha Gene Therapies stock opened at $5.96 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. The firm has a fifty day moving average price of $5.31 and a 200 day moving average price of $4.99. Taysha Gene Therapies has a 1 year low of $2.25 and a 1 year high of $7.30. The stock has a market cap of $1.71 billion, a PE ratio of -15.68 and a beta of 1.25.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities research analysts predict that Taysha Gene Therapies will post -0.48 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.